Soleno Therapeutics Inc.

SLNO | NASDAQ

Price Alert Chart Builder DCF Calculator

$53.01

$0 (0.00%)

At close: May 15, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $2.76B

Enterprise Value $2.51B

Beta -2.22

Average Volume 3.37M

Shares Outstanding (Diluted) 53.07M

Shares Change YoY 14.92%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US8342033094

Price Performance

Price Change 1M 0.5%

Price Change 3M 34.5%

Price Change 6M 17.5%

Price Change YTD 12.4%

Price Change 1Y -29.4%

Price Change 3Y 101.9%

Price Change 5Y -31.4%

1M CAGR (ann.) 1.4%

1Y CAGR (ann.) -29.4%

5Y CAGR (ann.) -7.6%

All-Time CAGR -25.0%

Valuation

PE Ratio 29.95

Forward PE 8.26

PEG Ratio 0.02

Forward PEG 0.44

PS Ratio 9.69

Forward PS 4.00

PB Ratio 5.57

P/FCF Ratio 26.16

P/Adj. FCF Ratio 40.41

P/OCF Ratio 26.11

EV/Sales 8.81

EV/EBIT 36.52

EV/EBITDA 24.73

EV/FCF 23.78

Earnings Yield 3.3%

FCF Yield 3.8%

Adj. FCF Yield 2.5%

Financial Health

Net Cash $251.19M

Total Debt $4.41M

Cash & Short-Term Investments $255.6M

Total Assets $608.39M

Current Ratio 5.62

Quick Ratio 5.32

Debt / Equity Ratio 0.01

Debt / EBITDA 0.04

Debt / FCF 0.04

OCF / Debt 23.99

Interest Coverage 16.23

Altman Z-Score 15.17

Piotroski F-Score 6

Margins & Profitability

Gross Profit Margin 98.6%

Operating Profit Margin 30.6%

EBITDA Margin 37.5%

Net Profit Margin 33.7%

FCF Margin 37.0%

Adj. FCF Margin 24.0%

SBC / Revenue 7.4%

SBC Impact (per share) -35.3%

Returns

Return on Assets 15.8%

Return on Equity 22.9%

Return on Invested Capital 15.3%

Return on Capital Employed 15.9%

Return on Tangible Assets 15.9%

Historical Growth (CAGR)

Revenue CAGR 3Y 150.0%

Revenue CAGR 5Y 100.0%

Revenue CAGR 10Y 79.7%

EPS CAGR 3Y 121.2%

EPS CAGR 5Y 44.6%

EPS CAGR 10Y 33.3%

FCF CAGR 3Y 1393.0%

FCF CAGR 5Y 156.9%

FCF CAGR 10Y 17.6%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 13

EPS Growth Next 3Y 79.9%

Revenue Growth Next 3Y 66.5%

Earnings Date Aug 4, 2026

EPS Estimate (next Q) $0.91

EPS Growth Est (next Q) -1111.1%

Revenue Est (next Q) $111.76M

Revenue Growth Est (next Q) 242.2%

Fair Value Estimates

Graham Number $19.47

Graham Upside -63.3%

Lynch Fair Value $44.25

Lynch Upside -16.5%

Price Target $53

Price Target Upside 0.0%

Cash Flow

Operating Cash Flow $105.71M

Free Cash Flow $105.6M

Adj. Free Cash Flow $68.38M

FCF Per Share $2.03

OCF Per Share $2.03

OCF/S Ratio 37.1%

Income Statement

Revenue $285.01M

Gross Profit $187.7M

Operating Income $87.29M

EBITDA $101.57M

Net Income $96.04M

EPS (Diluted) $1.77

Revenue / Employee $2.48M

Profit / Employee $835.14K

Employees 115